Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Bounthavy Homsombath

Surgical Critical Care Augusta, GA Medical Doctor

NPI 1225281330 CMS profile 1251918

3675 J Dewey Gray Cir, Suite 300, Augusta, GA 30909

Open in the dashboard

General payments

$29,985

27 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,500 paid to institutions, not to them · program year 2021

Through program year 2025, Bounthavy Homsombath of Augusta, GA is reported in the CMS Open Payments database as having received $29,985 across 27 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Surgical Critical Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $375 5
2024 General $23 1
2023 General $12,996 6
2022 General $5,887 7
2021 General $10,388 4
2020 General $316 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bounthavy Homsombath
  • Surgical Critical Care median
  • Middle half of Surgical Critical Care
  • National median

In program year 2025, general payments to Bounthavy Homsombath were reported at $375. Among 1,068 Surgical Critical Care profiles paid that year, the median was $231 and the middle half received between $82 and $1,489.

Show as a table
Year Bounthavy Homsombath Surgical Critical Care median Middle half National median
2019 $0 $161 $57–$631 $163
2020 $316 $116 $33–$383 $114
2021 $10,388 $121 $37–$475 $132
2022 $5,887 $163 $53–$789 $149
2023 $12,996 $188 $67–$1,031 $160
2024 $23 $216 $80–$1,133 $164
2025 $375 $231 $82–$1,489 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Vericel Corporation $28,260 7 payments
  2. Kerecis Limited $775 5 payments
  3. Avita Medical Americas, LLC $282 2 payments
  4. Medline Industries, Inc. $148 2 payments
  5. Access Pro Medical, LLC $144 1 payment
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $124 1 payment
  7. Smith+Nephew, Inc. $88 5 payments
  8. Trevena, Inc. $80 1 payment
  9. PolyNovo North America LLC $32 1 payment
  10. Mallinckrodt Hospital Products Inc. $30 1 payment
  11. Other $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $18,000 3 payments
  2. Education $10,000 1 payment
  3. Food and Beverage $1,985 23 payments
Products named General payments · program years 2020–2025
  1. EPICEL (CULTURED EPIDERMAL AUTOGRAFTS) $18,205 4 payments
  2. Epicel $10,000 1 payment
  3. Kerecis Omega3 SurgiClose Wound Care $392 1 payment
  4. Kerecis Omega3 GraftGuide $392 1 payment
  5. Kerecis Omega3 SurgiClose Wound Care $392 1 payment
  6. Kerecis Omega3 Marigen $392 1 payment
  7. Kerecis Omega3 SurgiClose Wound Care $392 1 payment
  8. Kerecis SurgiClose Wound Care $199 3 payments
  9. Kerecis SurgiClose Wound Care $199 3 payments
  10. Kerecis SurgiClose Wound Care $199 3 payments
  11. Other $2,112 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

203

Median for General Surgery: 59

Drug cost

$1,169

Median for General Surgery: $393

Branded share of claims

63.5%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 75 $477
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 54 $368
Oxycodone Hcl Generic 55 $180
Mupirocin Generic 19 $143

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$217,838

Medicare's payments for the services billed

Medicare patients

214

Average age 68

Services billed

2,651

96 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Arthritis 45%
Chronic kidney disease 43%
Depression 37%
Heart failure 36%
Ischemic heart disease 34%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgical Critical Care in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record